A drug which helps treat patients suffering from refractory metastatic colorectal cancer with nonmutated (wild-type) KRAS genes is being recommended for use in the EU.
The EMEA’s Committee for Medicinal Products for Human Use (CHMP) has said conditional marketing authorisation should be granted for Vectibix® (panitumumab), which is manufactured by Amgen.
Vectibix is the first fully human IgG2 monoclonal antibody (MAb) which targets the epidermal growth factor receptor (EGFr), a protein that plays an important role in cancer cell signalling.
Phase III trials are now exploring the potential of administering Vectibix in combination with chemotherapy for first- and second-line metastatic colorectal cancer.
Dr Willard Dere, senior vice-president and international chief medical officer at Amgen, commented: “We are pleased that Vectibix has received a positive opinion for conditional approval so patients in the EU have further treatment options for metastatic colorectal cancer. This is an important step forward in personalised cancer care.”
Copyright © PA Business 2007